Testing a new drug for Parkinson's disease
Part of Blood & lymphatic, Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This study tests an experimental drug, MTX325, in people with Parkinson's disease. The goal is to see if it is safe and how the body processes it, which may lead to new treatment options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 75 years old.
- You have been diagnosed with Parkinson's disease by a doctor.
- You are not living in a nursing home or assisted care facility.
- You have not had more than 2 freezing episodes or falls related to Parkinson's in the past 6 months.
- You can have a lumbar puncture (spinal tap) and do not have conditions that make it risky.
- You are not currently taking Parkinson's disease medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests several experimental drugs at once to find new treatments for Parkinson's disease. If you have Parkinson's and take medication, you may be able to join and help speed up research.
This trial tests a new drug called VT-5006 to see if it is safe for people with Parkinson's disease. It focuses on those who have stomach or bowel issues, like constipation.
This study tests whether an experimental oral medication (TJ0113) can improve symptoms in people diagnosed with Parkinson's disease before age 50. Participants must already be taking levodopa and keep their current Parkinson's medications unchanged during the study.
This study tests an investigational imaging agent called SST001, which may help doctors see a protein linked to Parkinson's disease (PD) and multiple system atrophy (MSA) in the body. It will be given to healthy volunteers and patients with PD or MSA to check safety, how it spreads, and how the body handles it.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This trial tests a new oral medicine, GT-02287, to see if it can help people with early Parkinson's disease. It aims to improve symptoms and slow the disease, and it also tracks how the medicine affects certain markers in the body.
Hear when a new Parkinson's Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.